Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Top Performing Drug – Tagrisso (October Edition)
Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Tagrisso and prepared a curated analysis report for our readers Tagrisso is indicated for the treatment of non-small-cell lung carcinomas with specific mutations. It is a 3rd generation drug that belongs to the…
October 25, 2023
Insights+: The US FDA New Drug Approvals in September 2023
Insights+: The US FDA New Drug Approvals in September 2023
Shots: The US FDA approved 7 NDAs and 2 BLAs in September 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 98 novel products in 2023 In September 2023, the major highlights drugs were Ojjaara (momelotinib) approval for myelofibrosis patients with anemia, and Entyvio (vedolizumab) for subcutaneous…
October 18, 2023
New Drug Designations - September 2023
New Drug Designations – September 2023
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota  MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
October 16, 2023
Disease of the Month- Osteoporosis
Disease of the Month- Osteoporosis
To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings a condensed report on Osteoporosis, a bone and tissue disorder  October 20th is observed as…
October 12, 2023
Insights+ Key Biosimilars Events of September 2023
Insights+ Key Biosimilars Events of September 2023
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients During the month of September, Sandoz entered into a development and commercialization agreement…
October 4, 2023
PharmaShots' Key Highlights of Third Quarter 2023
PharmaShots’ Key Highlights of Third Quarter 2023
Shots: Third quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, Biogen acquired Reata Pharmaceuticals for ~$7.3B and Danaher acquired Abcam for ~$5.7B The third quarter of the year also showcases multiple clinical trial results which include Janssen reported P-IIb…
October 2, 2023
Insights+: EMA Marketing Authorization of New Drugs in August 2023
Insights+: EMA Marketing Authorization of New Drugs in August 2023
Shots: The EMA approved 5 New Chemical Entity (NCE) and 6 Biologic Drugs in August 2023, leading to treatments for patients and advances in the healthcare industry In August 2023, the major highlight drugs were Aquipta (atogepant) approved for the preventive treatment of migraine in adults & Opdivo (nivolumab) as an adjuvant treatment for completely…
September 28, 2023
Know Your Investor: F-Prime Capital Partners
Know Your Investor: F-Prime Capital Partners
Shots: PharmaShots' tertiary report on the Know Your Investor Section features F-Prime Capital Partners. Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare…
September 28, 2023
Top Performing Drug – Ozempic (September Edition)
Top Performing Drug – Ozempic (September Edition)
Shots:  PharmaShots’ next episode on the top-performing drug of the month, based on 2021 revenue, focuses on Ozempic, a drug developed and marketed by Novo Nordisk    Ozempic (semaglutide) is a human GLP-1 receptor agonist (or GLP-1 analog). It, when taken along with diet and exercise, is proven to improve blood sugar in adults with type 2…
September 27, 2023
Insights+: The US FDA New Drug Approvals in August 2023
Insights+: The US FDA New Drug Approvals in August 2023
Shots: The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023 In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…
September 20, 2023
Load more